Potential Target Antigens for a Universal Vaccine in Epithelial Ovarian Cancer

Renee Vermeij; Toos Daemen; Geertruida H. de Bock; Pauline de Graeff; Ninke Leffers; Annechien Lambeck; Klaske A. ten Hoor; Harry Hollema; Ate G. J. van der Zee; Hans W. Nijman

doi:10.1155/2010/891505

Clinical and Developmental Immunology (Jan 2010)

Potential Target Antigens for a Universal Vaccine in Epithelial Ovarian Cancer

Renee Vermeij,
Toos Daemen,
Geertruida H. de Bock,
Pauline de Graeff,
Ninke Leffers,
Annechien Lambeck,
Klaske A. ten Hoor,
Harry Hollema,
Ate G. J. van der Zee,
Hans W. Nijman

Affiliations

Renee Vermeij: Department of Gynecological Oncology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands
Toos Daemen: Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands
Geertruida H. de Bock: Department of Epidemiology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands
Pauline de Graeff: Department of Gynecological Oncology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands
Ninke Leffers: Department of Gynecological Oncology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands
Annechien Lambeck: Department of Gynecological Oncology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands
Klaske A. ten Hoor: Department of Gynecological Oncology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands
Harry Hollema: Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands
Ate G. J. van der Zee: Department of Gynecological Oncology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands
Hans W. Nijman: Department of Gynecological Oncology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands

DOI: https://doi.org/10.1155/2010/891505
Journal volume & issue: Vol. 2010

Abstract

Read online

The prognosis of epithelial ovarian cancer (EOC), the primary cause of death from gynaecological malignancies, has only modestly improved over the last decades. Immunotherapeutic treatment using a cocktail of antigens has been proposed as a “universal” vaccine strategy. We determined the expression of tumor antigens in the context of MHC class I expression in 270 primary tumor samples using tissue microarray. Expression of tumor antigens p53, SP17, survivin, WT1, and NY-ESO-1 was observed in 120 (48.0%), 173 (68.9%), 208 (90.0%), 129 (56.3%), and 27 (11.0%) of 270 tumor specimens, respectively. In 93.2% of EOC, at least one of the investigated tumor antigens was (over)expressed. Expression of MHC class I was observed in 78.1% of EOC. In 3 out 4 primary tumors, (over)expression of a tumor antigen combined with MHC class I was observed. These results indicate that a multiepitope vaccine, comprising these antigens, could serve as a universal therapeutic vaccine for the vast majority of ovarian cancer patients.

Published in Clinical and Developmental Immunology

ISSN: 1740-2522 (Print); 1740-2530 (Online)
Publisher: Hindawi Limited
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: https://www.hindawi.com/journals/jir/

About the journal